Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

ASTRAZENECA PLC (AZN)

98
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
React to this article
Latest news on ASTRAZENECA PLC
09:13a ASTRAZENECA : Says FDA Approves New Administration Option For BRILINTA
09:07a ASTRAZENECA : BRILINTA Receives US FDA Approval for New Administration Option
08:32a ASTRAZENECA : Maryland Regional Biotech Forum Aims to Propel Washington, D.C. Me..
03/26 AstraZeneca, Glaxo Sign Up For 100,000 Genomes Project Consortium
03/26 ASTRAZENECA : joins Genomics England consortium
03/26 ASTRAZENECA : Reports Results from PEGASUS-TIMI 54 Study
03/25 ASTRAZENECA : joins Genomics England consortium
03/25 FIBROGEN : Announces 2014 Financial Results and Provides Corporate Update
03/25 ASTRAZENECA : Inks Collaboration With Harvard Stem Cell Institute
03/25 ASTRAZENECA : and Daiichi Sankyo to jointly commercialise MOVANTIK in the US
Advertisement
Chart
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF